HMN 2026: How Switching from dulaglutide to tirzepatide boosts patient-reported well-being for people with type 2 diabetes: Analysis

An analysis of patient-reported outcomes (PROs) from the SURPASS-SWITCH trial found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide not only saw stronger improvements in blood sugar and weight but also reported feeling emotionally better.

The findings suggest that greater clinical effects of type 2 diabetes drugs may be associated with a greater quality of life (QoL) for patients. The study is published in Annals of Internal Medicine.

Researchers from Eli Lilly and Company aimed to report PROs from SURPASS-SWITCH measuring health- and weight-related QoL, including a novel measure of the emotional effect of diabetes treatment.

In this 40?week randomized study, adults with type 2 diabetes who weren’t achieving good blood sugar control on dulaglutide were assigned either to continue increasing their dulaglutide dose or to switch to tirzepatide.

Researchers used several patient?reported outcome measures to assess weight-related self?perception, ability to perform daily activities, and emotional responses to treatment. Both groups improved, but those who switched to tirzepatide reported greater gains across nearly all measures.

These patients felt more positive, more in control of their condition, and less fearful or frustrated. The findings suggest that tirzepatide may offer broader benefits beyond glucose control, helping patients feel better physically and emotionally in their day?to?day lives.

The content is provided for information purposes only.